Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 8, 1997

View Archived Issues

Lilly synthesizes antiobesity proteins

Tokyo Tanabe describes agents for cardiovascular/respiratory disorders

Prokinetic agents from Tokyo Tanabe

Anti-HCV agents revealed by Japanese and Chinese investigators

Zeneca describes nonpeptide antagonists of NK2 receptors

Hoechst Japan describes immunosuppressive peptides

Allervax Cat moves towards commercialization

New form of DNA linked to prostate cancer

Neurobiological Technologies discontinues development of antiarthritic agent

Multikine enters clinical testing in AIDS patients

Draxis acquires Canadian rights to Mylan's paclitaxel formulation

Bimoclomol progresses in trials

Joint venture ends

Preclinical pharmacology profile of BMS NEP/ACE inhibitors described

Genzyme Transgenics, BASF forge agreement for transgenic production of biopharmaceuticals

Tri-Point seeks FDA approval for TraumaSeal

Roberts to market Lodine in U.K. and Ireland

Leptin triggers reproductive function

Caliper Technologies technology useful in drug discovery

Dexketoprofen trometamol: An NSAID with improved safety and efficacy

Celtrix completes phase I studies of SomatoKine

Pharmacyclics completes phase I testing of Lu-Tex

Immune Response announces results for rheumatoid arthritis Rx

Study results reported for Immune Response antipsoriatic agent

Oxis International completes phase I testing of IBD treatment

Digene seeks FDA marketing approval for cytomegalovirus test

Comparative clinical trials with Viracept

IAF BioVac vaccine R&D in review

BCH-4556 slated to enter clinical testing

Nasalcrom cleared by FDA as OTC

New analgesic drug candidate emerges from BioChem Pharma/Astra collaboration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...